sorry, I missed answering your Q:
- No, I not have checked production capacity of all of the AU TGA approved RDTs (as they are 40+ now counting imported branded, not just AU company owned/manufactured; all approved ones would be hassling the AU gov + private sectors for take-up...whether they have good or avg accuracy and price).
Anyway, think there has been some recent confusion on these threads about AT1 test production capacity in relation to the Covid19 Ag test kit. The Ag kit is rebranded by AT1 as its made by our Access Bio partner (in US factories; the reagents, plastic bits for the kits come from China, Korea etc). Access Bio production capacity should already be >30m Ag kits per Qtr currently (this is my low estimate based on several m's of kits ordered since Oct'20 in their KRX ann).
See the Qtrly conference notes today for AT1's specific device production/capacity numbers...those are relevant for the other test agreements like HIV, NG Bio Ab, AccBio Ab, NG Bio pregnancy, Lumos Dx FebriDx, potential India market Ab test supply, any ongoing R&D, new digital device dev etc (and seems like there is no problems in providing required quantities or implementing further scale-up as needed for biz growth, from today's briefing):
sorry, I missed answering your Q:- No, I not have checked...
-
- There are more pages in this discussion • 1,210 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
